Another Genmab drug from Janssen receives breakthrough therapy designation

The US FDA has given breakthrough therapy status to the cancer drug teclistamab which is based on Genmab's Duobody platform.

Photo: Joost Melis / Genmab / PR

Shortly after Janssen secured approval from the US Food and Drug Administration (FDA) for the Genmab-developed lung cancer drug Rybrevant, the pharmaceutical company has taken a crucial step with another drug from Genmab's Duobody platform.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

China approves Y-mabs drug

Y-mabs’ cancer treatment Danyelza, which is currently licensed to Sciclones, has been approved by the Chinese authorities. Y-mabs will receive double-digit sales royalties.

Further reading

Related articles

Latest news

See all jobs